key: cord-0871856-lbuzzlap
authors: Elec, Florin; Magnusson, Jesper; Elec, Alina; Muntean, Adriana; Antal, Oana; Moisoiu, Tudor; Cismaru, Cristina; Lupse, Mihaela; Oltean, Mihai
title: COVID-19 AND KIDNEY TRANSPLANTATION: THE IMPACT OF REMDESIVIR ON RENAL FUNCTION AND OUTCOME- A RETROSPECTIVE COHORT STUDY
date: 2022-03-14
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2022.03.015
sha: 725fc6694c3431b4f478307f56e6ccb16984d50c
doc_id: 871856
cord_uid: lbuzzlap

Objectives : The aim of the study is to evaluate the impact of remdesivir on overall mortality, ICU mortality and renal functional outcome in hospitalized Covid 19 kidney transplant patients. Methods : We reviewed 165 KTx hospitalized due to COVID-19 between March 1, 2020, and May 31, 2021. Thirty-eight KTx received a five-day RDV treatment while 127 received standard of care (SOC). Overall and ICU mortality along with functional outcome were assessed. Results : The two groups had similar baseline characteristics. RDV treatment was completed in all patients without any adverse effects attributable to RDV. In terms of overall mortality, there was no difference between the RDV and SOC groups (18% vs 23%, p>0.05), but the ICU mortality was significantly reduced in the RDV group (38% vs 29%, p<0.05). RDV seems to have no nephrotoxic effect on TxR patients, as there was no difference in the incidence of AKI between RDV and SOC groups (50% vs 43%, p<0.05), and the discharge eGFR values significantly improved in the RDV group compared with the admission values (57±23 vs 44±22, p<0.05). Conclusion : Five-day RDV treatment appears safe in KTx recipients and may decrease ICU mortality attributed to COVID-19 and has no nephrotoxic effect.

Lifelong immunosuppression and the burden of comorbidities put organ transplant recipients at risk for unfavourable outcome following SARS-CoV-2 infection (Qin et al, 2021 , Jager et al, 2020 . The initial lack of knowledge concerning this new and puzzling disease as well as the absence of targeted and effective antiviral interventions during the early phases of the pandemic, resulted in a mortality of kidney transplant KTx recipients exceeding 25% (Oltean et al, 2020) . However, rapidly accumulating information, evolving guidelines and several experimental treatments seem to have improved the outcomes following COVID-19 both in transplanted patients and the general population (Heldman et al, 2021 , Elec et al, 2021 , Villanego et al, 2021 . Remdesivir (RDV), a broad-spectrum antiviral agent initially developed to treat hepatitis C and Ebola virus disease (Lo et al, 2017) , remains one of the few evidence-based targeted antiviral interventions available to date.

The urgency required in the development and review of several new anti-COVID 19 compounds, including RDV, has led to the exclusion of several risk groups from the trials conducted during 2020, such as patients with poor liver and kidney function (creatinine clearance less than 30 or 50 mL/min) (Beigel et al, 2020 , Goldman et al, 2020 , Spinner et al, 2020 . This caution was largely justified by concerns related to previously known side effects such as potential nephrotoxicity of RDV or its inactive ingredient, the solubility enhancer sulfobutylether-β-cyclodextrin (SBECD), which can accumulate in patients with impaired renal function (Luke et al, 2010) . Unfortunately, this has also resulted in a knowledge gap about the safety, optimal dosing and efficacy of RDV in patients with reduced renal function.

Hence, the impact of RDV on COVID-19 outcome in KTx recipients, which frequently have impaired renal function, is poorly known.

There are very few reports on the use of RDV in KTx recipients with COVID-19 (Elec et al, 2021 , Buxeda et al, 2021 , Meshram et al, 2021 . This limited body of evidence generated from widely different geographic areas during various pandemic phases could not discern significant side effects and suggests that RDV was well tolerated and safe in kidney transplant recipients with COVID-19. However, its impact on the overall outcomes and comparison with patients receiving the standard of care (SOC) is essentially missing, as only one small study attempted to balance its findings (outcome, biochemistry) against a control group of KTx with COVID-19 not receiving RDV (Elec et al, 2021) . Here, we comparatively analyzed a cohort of KTx recipients with COVID-19 and receiving RDV or not during the same time span period at a transplant centre in Eastern Europe. The main readouts of this study were overall mortality, ICU mortality and functional outcome.

We performed a retrospective cohort single centre study of all KTx recipients who 

The COVID-19 treatment protocol recommended in Romania in the early phase of the pandemic (March-July 2020) was based on hydroxychloroquine (HCQ) and antiretrovirals.

HCQ was started with a loading dose of 400 mg orally twice daily for one day and then continued at 200 mg orally twice daily for 7-10 days. Antiretrovirals (lopinavir/ritonavir, darunavir/ritonavir, or darunavir/cobicistat) were added in patients with mild and moderate forms and adequate renal function (estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m 2 ). From mid-July 2020, RDV was added to the treatment protocol in more severe cases, while HCQ and antiretrovirals were no longer recommended. When available, RDV (Veklury, Gilead Pharma) was administered in moderate and severe cases applying the five-day European Medicines Agency protocol (European Medicines Agency, 2020). Low eGFR and AKI were not considered as contraindications. RDV was started at a dose of 200 mg/day on the first day, followed by 100 mg/day over the next four days, given as an intravenous infusion. Dexamethasone and antibiotics were also given at the discretion of the medical teams attending the patients. Anticoagulation using low molecular weight heparin (LMWH) was recommended in all hospitalized patients from mid-April 2020 onward.

Antibiotics were given at the discretion of the attending medical teams. Immunosuppression was managed through contacts with the transplant nephrologists from CIURT.

Immunosuppression was frequently reduced, by pausing the antimetabolite (mycophenolate mofetil or mycophenolic acid) with or without adjusting calcineurin inhibitors. Tacrolimus was withdrawn in all patients receiving antiretrovirals and adjusted to maintain a trough level of 4-6 ng/mL in the other patients. Steroids were either kept at the maintenance dose or converted to IV for stress dosing. Other therapies like tocilizumab were given as per the local availability and severity of COVID-19.

The following data was recorded as baseline characteristics of the two groups: sex, age, weight, body mass index (BMI), comorbidities (hypertension, cardiovascular disease, diabetes, malignancy), baseline and hospital admission renal function (estimated glomerular filtration rate (eGFR) using the CKD-EPI formula; baseline eGFR was collected during the last 12 months before COVID-19), Charlson comorbidity index (CCI) as previously described (Oltean et al, 2012) , time from transplant, baseline immunosuppression, and treatment administered for COVID-19 management. The following data was recorded as outcomes: overall mortality, ICU mortality, COVID-19 severity (classified from mild to critical using the NIH criteria (Coronavirus Disease 2019 COVID-19 treatment guidelines, 2020)), ICU admission, oxygen therapy, mechanical ventilation, acute kidney injury (AKI) incidence during hospitalization (defined as an increase in serum creatinine by 0.3 mg/dl or more within 48 hours or as an increase of 1.5 times or more from baseline), discharge eGFR.

Demographic, baseline characteristics and outcomes were assessed as counts and percentages for categorical values and as a mean (±standard deviation) or median (±range) for continuous variables. Fisher's exact test was used to assess the proportions of categorical variables. Continuous variables were assessed using the Mann-Whitney U test. Kaplan-Meier and the log-rank test were used to calculate and compare survival.

Age, sex, comorbidities, chronic kidney disease grade 4-5 (baseline eGFR <30 ml/min/1.73m 2 ), time from transplantation and BMI were chosen as potential risk factors based on hypotheses and/or prior studies showing a relationship with Covid-19 mortality.

Analyses were performed using GraphPad Prism v.9.3. (GraphPad Software, San Diego, CA)

At the start of the pandemic (March 1 st , 2020), 1467 KTx recipients were alive and in followed-up at the Institute of Urology and Renal Transplantation in Cluj-Napoca, Romania.

Further, 51 patients were transplanted during the study period, resulting in a total of 1518 KTx recipients at risk for developing COVID-19 which were included in this study. During the 15 months of the study, there were 234 KTx recipients diagnosed with COVID-19 (15,7%). 59 patients (25%) were managed entirely on an outpatient basis and were excluded from the analysis. Further, 10 patients received favipiravir and were excluded from the analysis. The remaining 165 hospitalized formed the basis for the current report: 38 (23%) patients received RDV as part of their COVID-19 management, whereas 127 (77%) did not (SOC group) ( Table 1) .

Patients in the two groups were largely similar in terms of age, time from transplantation, frequency of obesity and comorbidities (Table 1) . However, the RDV group included less male subjects (55% vs 70%, p<0.05), more patients with grade G3a kidney disease (36.8 vs 16.5%, p<0.05), more diabetes patients (47% vs 24%, p<0.05), and malignancies (7.9% vs 0.8%, p<0.05) ( Table 1 ). In terms of baseline immunosuppression, the RDV group had more patients on Rapamycin (11% vs 2%, p<0.05) ( Table 1 ). In terms of COVID-19 management, the RDV group had less Mycophenolate mofetil reduction or withdrawal (37% vs 58%, p<0.05), and administration of low-molecular-weight heparin and non-vitamin K antagonist (84% vs 86%, p<0.01), while more patients were administered Tocilizumab and Dexamethasone (11% vs 2%, p<0.05, and 84% vs 41%, p<0.05, respectively) ( Table 1) .

In terms of overall mortality, there was no difference between the RDV and SOC groups (18% vs 23%, p>0.05) (Table 2, Figure 1A and B), but the ICU mortality was significantly reduced in the RDV group (38% vs 29%, p<0.01) (Table 2, Figure 1 C and D) . The proportion of patients with severe COVID-19 was higher in the RDV group (42 % vs 14%, p<0.05), while the proportion of patients with mild COVID-19 disease was lower in the RDV group (8% vs 36 %, p<0.05) (Table 2, Figure 2A ). In addition, the proportion of patients requiring ICU admission was significantly higher in the RDV group compared with patients receiving SOC (47% vs 27%, p<0.05).

Univariate analysis for mortality showed significant differences between survivors and nonsurvivors for the following confounding factors: the number of patients aged over 65 (HR: 2.51 (1.11 -5.14), p<0.05), CCI (HR 1.81 (1.06 -1.6), p<0.05), recent transplant (<12 months) 11 (HR 2.4 (0.96 -5.21), p<0.05), stage 4-5 chronic kidney disease at baseline (HR 3.81 (1.96 -7.35), p<0.05). In multivariate Cox regression, the following confounding factors reached statistical significance for association with shorter survival: recent transplant (<12 months)

[HR 3.14 (1.07 -8.77), p<0.05), stage 4-5 chronic kidney disease at baseline (HR 7.49 (3.25 -17.9), p<0.05) and COVID-19 severity (HR 8.12 (4.32-18.2), p<0.05).

Supplemental oxygen was required significantly more often in patients receiving RDV compared with patients receiving SOC (84% vs 44%, p<0.05), and there was no difference in the proportion of patients requiring mechanical ventilation (21% vs 24%, p>0.05) ( Table 2) .

No serious adverse effects attributable to RDV were noted, and the five-day RDV treatment was completed in all patients.

At hospital discharge, there was no sign of RDV nephrotoxicity, with no difference in the incidence of AKI between RDV and SOC groups (50% vs 43%, p>0.05), while the admission eGFR values significantly improved in the RDV group compared with the discharge values (Table 2, Figure 2B -C). There was no difference in the discharge eGFR between RDV and SOC groups (57±23 vs62±28 ml/min/1.73m2, p>0.05) ( Table 2) .

This study reports the outcomes of hospitalized kidney transplant recipients with COVID-19 treated with RDV compared with patients receiving SOC alone. The results suggest that RDV has a positive impact on COVID-19 patients in terms of ICU mortality and that the drug is not associated with significant nephrotoxicity. Consequently, these results suggest that recommendations on RDV use in the normal populations could be extended to RTx recipients.

The landmark paper of Beigel et al. has provided essential knowledge about optimal dosing and timing, adverse effects and outcomes of RDV (Beigel et al, 2020) . Currently, RDV is recommended in hospitalized patients requiring supplementary oxygen (i.e., severe disease forms) but not mechanical ventilation, with or without dexamethasone, as a five-or ten-days treatment protocol, administered as soon as possible after the onset of symptoms, and preferably within the first week. However, as severe Covid-19 typically becomes manifest eight to twelve days after symptom onset, it is possible that in some patients, including patients in this study, RDV administration was initiated late in the course of the disease.

Hence, the window of opportunity in the first days after infection, when intense viral replication occurs, can easily be missed. The median time from onset of symptoms and diagnosis and treatment start was within this time frame, and although several patients received RDV after more than ten days from the first symptoms, they all survived.

The current study suggests that RDV significantly decreased ICU mortality, possibly limiting disease progression. This finding is in line with several much larger studies in nontransplanted patients where RDV reduced the odds of death during the study and shortened the time to clinical recovery, particularly in hospitalized patients requiring oxygen supplementation but who were not in very critical condition (intubated or on extracorporeal membrane oxygenation) (Beigel et al, 2020 , Olender et al, 2021 . Impaired renal function following RDV treatment has been the main concern because of the potential accumulation, and renal tubule toxicity of RDV's active metabolite or its inactive ingredient SBECD used to improve its aqueous solubility (Luke et al, 2010) . Consequently, all initial studies on RDV have excluded patients with kidney impairment (estimated GFR < 30-50 ml/min/1.73m 2 ), an exclusion criterion that has led to a gap of knowledge in terms of efficacy and safety of RDV in this vulnerable patient group, especially TxR patients.

In this study, there was no difference in terms of AKI incidence for RDV and SOC groups (50% vs 43%, p>0.05). Similarly, to previous reports, the short RDV course applied in this study did not add to the other causes of renal impairment, such as dehydration, viral tropism, endothelial dysfunction, coagulopathy or systemic inflammation (Buxeda et al, 2021 , Meshram et al, 2021 . Moreover, there was an improvement in renal function during the hospitalization, the discharge eGFR being significantly increased compared to baseline ( Figure 2C ). This apparent improvement, likely due to several factors such as the decrease or discontinuation of calcineurin inhibitors, rehydration, and resolution of the disease, did not seem negatively affected by RDV.

RDV is metabolized by the cytochrome P450 3A4, similarly with tacrolimus. Although no apparent drug-drug interactions (DDI) are expected between RDV and tacrolimus (Deb et al, 2021) , some cytokines such as IL-1, IL-6 or interferon-gamma may downregulate cytochrome P450 (CYP) enzyme activity (Harvey et al, 2014) which may theoretically result in supratherapeutic levels of both RDV and tacrolimus. In contrast with lopinavir/ritonavir (Kaletra ®), which has been frequently used during the first months of the pandemic, and where DDI between it and numerous drugs, including tacrolimus, are well known, this concern has been largely theoretical during the use of Remdesivir (Elens et al, 2020 ). In addition, in patients with severe and critical disease, in which the "cytokine storm" could have developed, tacrolimus administration was frequently reduced or even discontinued (Maggiore et al, 2020) .

This study has several significant limitations. Until October 2020, the length of hospitalization for individuals infected with SARS-CoV-2 in Romania was regulated through a governmental ordinance to at least ten days of hospitalization or fourteen days from the start of symptoms, even if the patients have recovered completely. Unfortunately, this ambitious measure which aimed at ensuring optimal isolation during and after it also turned the length of hospital stay into an irrelevant outcome measure for over half of the study period.

The relatively small size, unequal distribution between groups and the retrospective design preclude solid conclusions, and the results need to be interpreted cautiously. Some relevant clinical or laboratory data (notably daily creatinine or liver function tests) could not be reliably assessed and compared as its availability was inconsistent between the two study groups. Kidney function and injury were assessed based only on serum creatinine, a widely available yet coarse parameter. In addition, although the groups were largely similar in terms of demographics, comorbidities, and immunosuppression, we found several significant differences in terms of kidney graft function, diabetes and malignancies, which may have reflected a certain selection bias. However, this selection bias did not favor the RDV group, which had worse baseline eGFR, and more diabetes and oncologic patients (Table 1 ). In spite of these circumstances, these patients had better ICU survival, which may suggest a certain benefit of RDV.

Despite these limitations, this analysis also has several strengths, notably the presence of a contemporary control group and the use of the same RDV treatment protocol throughout the study. The study population matched well with other larger studies or meta-analyses in terms of patient age, comorbidity burden and overall results (ICU admission rate, mortality) (Oltean et al, 2020 , Chen et al, 2021 , Jayant et al, 2021 . Although the study period stretched over three pandemic waves and presents an evolutionary experience where COVIDtreatment protocols have changed over time (Elec et al, 2021 , Villanego et al, 2021 , patients in the two study groups received simultaneously, albeit not randomized, either RDV or standard of care according to the recommendation at that point in time.

In conclusion, this study indicates that RDV was safe and well-tolerated in KTx recipients with COVID-19. Its administration did not appear to negatively impact the renal outcome of KTx. Although the ability of RDV to improve the overall mortality remains unclear, there may be a certain patient subgroup with non-critical disease that may benefit from RDV treatment.

There are no conflicts of interests to be reported

The study was reviewed and approved by the Ethical Review Committee of the Clinical Institute for Urology and Renal Transplantation (01/2021).

There is no funding source to be reported. hydroxychloroquine; LMWH -low molecular weight heparin; NOAC-novel oral anticoagulants; Abbreviations: ICU-intensive care unit; SD-standard deviation; AKI-acute renal injury; SDstandard deviation.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19

ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 -Final Report

Improved survival among hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. A nationwide population-based cohort study

Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19

Incidence of Mortality, Acute Kidney Injury and Graft Loss in Adult Kidney Transplant Recipients with Coronavirus Disease 2019: Systematic Review and Meta-Analysis

Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential

Remdesivir and Mortality in Patients with COVID-19

COVID-19 after kidney transplantation: Early outcomes and renal function following antiviral treatment

Comparing the First and Second Wave of COVID-19 in Kidney Transplant Recipients: An East-European Perspective

Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions

Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents

Limaye AP; UW Covid-19 SOT Study Team. Changing Trends in Mortality Among Solid Organ Transplant Recipients Hospitalized for Covid-19 During the Course of the Pandemic

Epub ahead of print

Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe

on Kidney Transplant Recipients in Pre-Vaccination and Delta Strain Era: A Systematic Review and Meta-Analysis

GS-5734 and its parent nucleoside analog inhibit Filo

Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD)

How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion

Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation

COVID-19) Versus a Cohort Receiving Standard of Care

Covid-19 in kidney transplant recipients: a systematic review of the case series available three months into the pandemic

Charlson's weighted index of comorbidities is useful in assessing the risk of death in septic patients

GS-US-540-5774 Investigators. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Abbreviations: SD-standard deviation; BMI-body mass index; eGFR -estimated glomerular filtration rate; CCI -Charlson comorbidity index ; CNI -Calcineurin inhibitors; HCQ -